within Pharmacolibrary.Drugs.ATC.G;

model G03FA12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.05,
    adminDuration  = 600,
    adminMass      = 0.0025,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Medroxyprogesterone and estrogen is a combination hormonal therapy primarily indicated for hormone replacement therapy in postmenopausal women to alleviate menopausal symptoms and to reduce the risk of osteoporosis. Medroxyprogesterone is a synthetic progestin, and estrogen (usually as conjugated estrogens or estradiol) is a natural female sex hormone. This combination is approved and used currently for hormone replacement therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult woman following oral administration of standard clinical doses. No published population pharmacokinetic model or clinical PK study directly reporting all parameters for this combination. Estimates are based on published PK for single agents.</p><h4>References</h4><ol><li><p>de Lignières, B (1999). Oral micronized progesterone. <i>Clinical therapeutics</i> 21(1) 41–2. DOI:<a href=&quot;https://doi.org/10.1016/S0149-2918(00)88267-3&quot;>10.1016/S0149-2918(00)88267-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10090424/&quot;>https://pubmed.ncbi.nlm.nih.gov/10090424</a></p></li><li><p>Järvinen, A, et al., &amp; Kela, M (2004). Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women. <i>Maturitas</i> 47(3) 209–217. DOI:<a href=&quot;https://doi.org/10.1016/j.maturitas.2003.01.001&quot;>10.1016/j.maturitas.2003.01.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15036491/&quot;>https://pubmed.ncbi.nlm.nih.gov/15036491</a></p></li><li><p>Barra, F, et al., &amp; Ferrero, S (2018). Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. <i>Expert opinion on drug metabolism &amp; toxicology</i> 14(4) 399–415. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2018.1461840&quot;>10.1080/17425255.2018.1461840</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29617576/&quot;>https://pubmed.ncbi.nlm.nih.gov/29617576</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03FA12;
